LENZ Therapeutics (LENZ) Receivables - Net (2025 - 2026)

LENZ Therapeutics (LENZ) posted quarterly Receivables - Net of $343000.0 for Q1 2026, up 4.26% quarter-over-quarter from $329000.0 in Q4 2025.

LENZ Therapeutics (LENZ) Receivables - Net (2025 - 2026) Analysis & Trends

LENZ Therapeutics (LENZ) has reported Receivables - Net for 2 consecutive years, with $343000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables - Net changed N/A year-over-year to $343000.0; the TTM figure through Mar 2026 stood at $343000.0 (changed N/A YoY), while the FY2025 annual figure was $329000.0, changed N/A from the prior year.
Receivables - Net climbed to $343000.0 in Q1 2026 per LENZ's latest filing, from $329000.0 in the prior quarter.
Across five years, Receivables - Net topped out at $343000.0 in Q1 2026 and bottomed at $329000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.64 Bn	130.78 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.89 Bn	77.90 Bn	3.93 Bn
3	Argenx Se	65.11 Bn	59.93 Bn	1.37 Bn
4	Moderna	55.83 Bn	50.69 Bn	52.00 Mn
5	BeOne Medicines	42.01 Bn	36.91 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.63 Bn	28.32 Bn	992.69 Mn
7	BioNTech SE	27.65 Bn	9.26 Bn	668.28 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn
9	Royalty Pharma	27.30 Bn	26.47 Bn	-
10	LENZ Therapeutics	147.15 Mn	147.15 Mn	5.21 Mn

Download Data